Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Overview News & Events Press Releases Events & Presentations Analyst Coverage Stock Information Stock Quote & Chart Financials & Filings SEC Filings Corporate Governance Documents & Charters Management Board of Directors Committee Composition Resources Investor FAQs Email Alerts Contact IR Press Releases Year None202220212020 Dec 06, 2022 Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer Nov 17, 2022 Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 Nov 10, 2022 Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights Nov 09, 2022 Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference Nov 02, 2022 Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights Oct 24, 2022 Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors Oct 13, 2022 Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform Oct 12, 2022 Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022 Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants Sep 12, 2022 Adagio Therapeutics Announces Corporate Name Change to Invivyd Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Year None202220212020 Dec 06, 2022 Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer Nov 17, 2022 Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19 Nov 10, 2022 Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights Nov 09, 2022 Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference Nov 02, 2022 Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights Oct 24, 2022 Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors Oct 13, 2022 Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform Oct 12, 2022 Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022 Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants Sep 12, 2022 Adagio Therapeutics Announces Corporate Name Change to Invivyd Pagination Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 10 of 23
Dec 06, 2022 Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete Schmidt, M.D., to Chief Medical Officer
Nov 17, 2022 Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
Nov 02, 2022 Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights
Oct 13, 2022 Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
Oct 12, 2022 Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
Sep 12, 2022 Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants
